Citius Oncology, Inc. (CTOR)
0.8516
+0.06
(+7.50%)
USD |
NASDAQ |
Sep 04, 15:11
Citius Oncology Shareholders Equity (Quarterly) : 40.38M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 40.38M |
| March 31, 2026 | 35.27M |
| December 31, 2025 | 58.41M |
| September 30, 2025 | 44.87M |
| June 30, 2025 | 32.40M |
| March 31, 2025 | 35.64M |
| December 31, 2024 | 41.29M |
| September 30, 2024 | |
| June 30, 2024 | 46.11M |
| March 31, 2024 | 45.86M |
| December 31, 2023 | 70.58M |
| Date | Value |
|---|---|
| September 30, 2023 | 69.54M |
| June 30, 2023 | 69.39M |
| March 31, 2023 | 68.77M |
| December 31, 2022 | 68.16M |
| September 30, 2022 | 0.0149M |
| June 30, 2022 | 0.0149M |
| March 31, 2022 | 0.0149M |
| January 31, 2022 | |
| October 31, 2021 | |
| July 31, 2021 | |
| April 30, 2021 | -0.0344M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Citius Pharmaceuticals, Inc. | 66.61M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 112.09M |
| Total Liabilities (Quarterly) | 71.71M |
| Debt to Equity Ratio | 0.2528 |
| Current Ratio | 0.7265 |
| Net Debt Paydown Yield | -1.86% |